Orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities that simultaneously targets VEGFR1-3 (IC50 values 34 nM, 21 nM, and 13 nM, resp.), PDGFRα and β (IC50 values 59 and 65 nM), and FGFR1-3 (IC50 values 69 nM, 37 nM, and 108 nM, resp). In addition, BIBF1120 also inhibits members of the Src family of tyrosine kinases, including Src, Lck, Lyn, and FLT-3 (IC50 values 156 nM, 16 nM, 195 nM, and 26 nM, resp.).

KEYWORDS: Nintedanib | supplier | RTK inhibitor | Angiokinase inhibitor | BIBF-1120 | BIBF1120 | Intedanib | CAS [656247-17-5] - [656247-18-6] | PDGF-FGF-VEGF | PDGFR | FGFR | VEGFR | Receptor tyrosine kinase | Src | Lck | Lyn | FLT-3 | antiangiogenic | antineoplastic | antitumor